Table 2.

MSC-based therapy clinical trials for sepsis.

NCT No.	Title	Status	Company Name	Disease/Conditions	Route of Administration	Intervention/Mechanism Target	Results	Phase
NCT02789995	Dysfunctions of human muscle stem cells in Sepsis	Completed	Institut Pasteur	Sepsis	Intravenous Donation	Study of patients with or without sepsis, blood and bone marrow sample and muscle biopsy	N/A	N/A
NCT02421484	Cellular immunotherapy for septic shock: A phase 1 trial (CISS)	Completed	Ottawa Hospital Research Institute	Sepsis	Intravenous	0.3 × 106, 1 × 106 and 3 × 106 cells/kg body weight was administered to participants	Single dose of MSCs demonstrated to be safe and was tolerated well.	1
NCT03369275	Cellular Immunotherapy for Septic Shock (CISS2)	Not yet recruiting	Ottawa Hospital Research Institute	Sepsis, Septic Shock	Intravenous	Participants will receive 3 × 108 BM- HMSCs	N/A	2
NCT01849237	Russian clinical trial of mesenchymal stem cells in patients with septic shock and severe neutropenia	Unknown	National Research center for Hematology	Sepsis	Intravenous	Participants will receive 1–2 × 106 MSC intravenous infusions up to 10 h after septic shock.	N/A	1 & 2
NCT02883803	Treatment of Severe Infections with Mesenchymal Stem Cells (CHOCMSC)	Not yet recruiting	Central Hospital Nancy France	Septic Shock	Intravenous	Participants will receive 1 × 106 cells/kg body weight after 12 h of septic shock	N/A	2
NCT02328612	Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharide in Human Volunteers (CELLULA)	Completed	Tigenix S.A.U	Sepsis	Intravenous	0.25 × 106, 1 × 106 and 4 × 106 cells/kg body weight were administered to different sets of participants	Intravenous infusion of the cells exhibited anti-inflammatory effects and proved to be safe and efficient	1

N/A = Not yet available.